As of this week, it has been four years since Emily received her T-cells. The first of Emily’s three days of T-cell infusions was administered on April 17, 2012. At that time, there was no way of knowing what the next day, even the next few hours, would bring, let alone the next four years. Emily was the first pediatric patient to receive T-cell therapy, and we are happy to report she was not the last.
Since Emily’s treatment, the clinical trial in which she was enrolled at Children’s Hospital of Philadelphia (CHOP) has had continued success. Recently, CHOP announced that they had treated their 100th patient in the cancer immunotherapy program.
As we reflect on the last four years, we would like to congratulate Dr. Stephan Grupp on his success with CHOP’s cancer immunotherapy program. Additionally, we are thrilled to see immunotherapy cancer research gain new strides as the number of cancers that are treatable increase and groundbreaking initiatives like the Parker Institute for Cancer Immunotherapy provide support.
Four years and 100 patients later, there is one thing that remains the same: We Believe!